Status:
TERMINATED
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Lead Sponsor:
Sumitomo Pharma Co., Ltd.
Conditions:
Small-cell Lung Cancer
Eligibility:
All Genders
70+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.
Eligibility Criteria
Inclusion
- Extensive-disease small-cell lung cancer
- Aged 70 years or older
- Performance status of 0-2
- No prior chemotherapy
Exclusion
- Prior therapy for primary lesion
- Pneumonitis and/or pulmonary fibrosis
- Active concomitant malignancy
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00286169
Start Date
April 1 2006
Last Update
April 12 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku Region Site
Chugoku, Japan
2
Chubu Region Site
Chūbu, Japan
3
Hokkaido Region Site
Hokkaido, Japan
4
Kanto Region Site
Kanto, Japan